Jing Li: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Jun Xu: Department of Gastroenterology, Peking University People's Hospital, Beijing, 100044, China.
Jiayang Jin: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Yuzhou Gan: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Yifan Wang: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Ruiling Feng: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Wenqiang Fan: Department of Rheumatology and Immunology, Xinxiang Central Hospital, Henan, 45300, China.
Yingni Li: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Xiaozhen Zhao: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Yucui Li: Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Shushi Gong: Department of Rheumatology and Immunology, Minda Hospital of Hubei Minzu University, Hubei, 445000, China.
Linchong Su: Department of Rheumatology and Immunology, Minda Hospital of Hubei Minzu University, Hubei, 445000, China.
Yueming Cai: Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518000, China.
Lianjie Shi: Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing, 100144, China.
Xiaolin Sun: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China. ORCID
Yang Xiang: Department of Rheumatology and Immunology, Minda Hospital of Hubei Minzu University, Hubei, 445000, China.
Qingwen Wang: Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518000, China.
Ru Li: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.
Jinxia Zhao: Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, China.
Yulan Liu: Department of Gastroenterology, Peking University People's Hospital, Beijing, 100044, China.
Junjie Qin: Promegene Institute, Shenzhen, 518110, China.
Zhanguo Li: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China. li99@bjmu.edu.cn.
Jing He: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China. hejing1105@126.com.
Alterations in intestinal microbiota have been identified as a key risk factor in Rheumatoid Arthritis (RA). This study presents a multidimensional gut microbiota profile from a large cohort of RApatients, stratified by disease stage and treatment regimens, and compared to healthy controls. Our dataset comprises gut microbiota profiles from 2,238 individuals, including 1,034 RApatients (Ascia Pacific RA cohort, APRAC) and 1,204 healthy controls. This dataset is enriched with detailed clinical metadata, including patient profiles, treatment histories, and environmental factors, providing a comprehensive "disease exposome" for RA. By integrating 16S rRNA gene sequencing with demographic, clinical, and environmental data, we offer a valuable resource to explore the complex relationships between gut microbiota and RA progression. This large-scale dataset is expected to be a foundation for collaborative research, advancing our understanding of the microbiome's systemic effects in RA and other autoimmune diseases and potentially guiding new therapeutic approaches.
References
Nature. 2006 Dec 21;444(7122):1027-31
[PMID: 17183312]
